Pymaceuticals Observations

When focusing the study of 250 mice down to those in four treatment groups (Capomulin, Infubinol, Ketapril and the Placebo control group) some conclusions can be made about the effectiveness of this study. Though the time life of the study is relatively short, 45 days, in comparison to the lifespan of a typical research mouse, a positive trend can be observed in the study of decreased tumor size with the Capomulin treatment. Over the 45-day study, the measured average tumor volume (mm3) for those mice treated with Capomulin decreased by approximately 20% from the initial average measured volume. In the same analysis, the other three treatment groups presented an increase in tumor volume. The mice treated with Infubinol and Ketapril presented a similar increase rate to that of the Placebo control group.

Over the shot study length, each trial group showed an increase in metastatic sites. Though the Capomulin group presents a possible slowing of metastasis, more timepoints of data are needed to determine if the observed trend is significant.